PHOX2B Mutant Brainstem Organoids for Hypoventilation Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of a well-established human model for congenital central hypoventilation syndrome (CCHS), hindering drug development efforts due to the inability to effectively screen and identify treatments for this life-threatening condition.
Innovation Solution
A hypoventilation physical model is created using brainstem and cerebral organoids derived from pluripotent stem cells with PHOX2B gene mutations, specifically incorporating polyalanine repeat expansions, to mimic the impaired ventilatory response to hypercarbia and hypoxemia, allowing for drug screening and treatment identification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mouse mutants are used to study CCHS, then CCHS-like phenotypes can be observed, but the models fail to fully recapitulate human disease and are limited in drug screening applicability
Solution Approach 1:
The patent creates human brainstem organoids that copy and replicate human CCHS disease pathology in vitro, using patient-derived pluripotent stem cells with PHOX2B mutations. This human-based organoid model replaces traditional mouse models, providing both disease accuracy and drug screening versatility simultaneously
Solution Approach 2:
The patent changes the biological system parameter from murine to human cells, and from in vivo to in vitro organoid culture. This parameter change enables the model to maintain human disease specificity while gaining the controllability and scalability needed for drug screening applications
2Adaptability or versatility
If traditional in vitro models are used, then drug screening can be performed, but they lack the physiological complexity of the brainstem respiratory centers
Solution Approach 1:
The patent transitions from traditional 2D cell culture to 3D organoid models, adding a spatial dimension that recapitulates the architectural complexity of brainstem respiratory centers. This dimensional change preserves physiological accuracy while maintaining the in vitro environment needed for drug screening
Solution Approach 2:
The patent segments the complex brainstem into specific functional organoid models (RTN organoids, nVII organoids) that focus on particular respiratory control circuits. This segmentation allows physiological accuracy in specific circuits while enabling modular drug screening approaches
3Reliability
If PHOX2B gene mutations are introduced, then CCHS disease mechanisms can be studied, but the complexity of polyalanine repeat expansions makes model standardization difficult
Solution Approach 1:
The patent extracts the specific pathogenic element (PHOX2B polyalanine repeat expansion) from the complex genetic background and focuses the organoid model on this discrete mutation. This extraction allows faithful representation of disease mechanisms while enabling standardized protocols around a specific, well-defined genetic alteration
Solution Approach 2:
The patent applies different polyalanine repeat lengths (+5Ala, +7Ala, +13Ala) to specific organoid lines to match different patient genotypes. This local quality approach maintains disease mechanism fidelity for each genotype while allowing standardized protocols to be applied within each mutation category
Data Source
AI summary
A hypoventilation physical model is provided. Particularly the physical model includes brainstem and cerebral organoids derived from pluripotent stem cells (PSCs) having a PHOX2B gene mutation. This mutation includes polyalanine repeat expansion mutations (PARMs), specifically 5-PARM, 7-PARM, and 13-PARM. These PARMs occur within a 20-alanine (20-Ala) polyalanine tract in exon 3 of the PHOX2B gene. The physical model provides a platform for studying impaired ventilatory responses and associated neuronal defects, offering a valuable tool for drug screening and the development of therapeutic strategies for hypoventilation syndromes.